AHP Pondimin Limitations Discussed With FDA While Redux Was Under Review
Wyeth-Ayerst informally discussed added limitations on Pondimin (fenfluramine) combination use while the Redux (dexfenfluramine) NDA was pending, former Wyeth-Ayerst Director-Medical Affairs Marc Deitch, MD, testified Sept. 7 during the ongoing diet-drug class action suit, Vadino v. American Home Products.
You may also be interested in...
Patients who used American Home Products' Redux or Pondimin for more than 60 days would be eligible to receive a cash payment of $6,000 if an echocardiogram shows heart valve regurgitation, while those who used the drugs for 60 days or less could receive $3,000, under a settlement proposed by AHP.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011